Battle Between Biopharmaceuticals & Biogenerics Give Insight Into Future Developments

Research and Markets have announced the addition of The Future Battle Between Biopharmaceuticals & Biogenerics Report to their offering

(PRWEB) November 15, 2003 --In this report we have analysed the opinions and arguments held by producers of biopharmaceuticals or generic-drug makers as well as regulatory authorities, in order to gain insight on how the near future guidelines will develop. We have reviewed the positions of the FDA and the EMEA, the views on regulatory precedent cases from the biologics industry, the possible route of a comparability study approval, the scope of clinical trial necessary, and the scientific and regulatory issues that must be addressedbefore future guidelines can be initiated.

This report has listed more than 50 approved recombinant products and their global sales figures. Furthermore, we have looked at expiring patents and the biogeneric products that are likely to get a head start in Europe and the US. The most active generic companies and their selected recombinant biologics project portfolio have been evaluated. This report also evaluates the key challenges faced by the generic companies, the expected prize of the second entry biologics, as well as the competitive strategies available to each respective party as they compete for market shares. To gain background and updated information, as well as standpoints from current leaders in this field, BioSeeker has interviewed a number of key management officers in the industry, key personnel of regulatory authorities, interest organizations, investors and members of the academic research community.

With growing pressure on capital health to make drugs more affordable, regulatory guidelines are necessary. Although some biopharmaceuticals have already lost their patent protection and are open to generic competition, the Biotech Industry Organization argues that producing biologics is still such a complex task that generic firms should have to prove their safety and effectiveness. This technical complexity coupled with the lack of regulatory pathways limits the number of generic drug producers capable of winning the battle against pharmaceuticals.

For a complete index of this report click on
http://www.researchandmarkets.com/reports/40094

About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com
or mailto:press@researchandmarkets.com
###